Zheng Manni, Wang Min
Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ann Transl Med. 2021 Jan;9(1):66. doi: 10.21037/atm-20-6073.
Heart disease is one of the leading causes of morbidity and mortality globally. To reduce morbidity and mortality among patients with heart disease, it is important to identify drug targets and biomarkers for more effective diagnosis, prognosis, and treatment. MicroRNAs (miRNAs) are characterized as a group of endogenous, small non-coding RNAs, which function by directly inhibiting target genes. The miR-15/107 family is a group of evolutionarily conserved miRNAs comprising 10 members that share an identical motif of AGCAGC, which determines overlapping target genes and cooperation in the biological process. Accumulating evidence has demonstrated the predominant dysregulation of the miR-15/107 family in cardiovascular disease, neurodegenerative disease, and cancer. In this review, we summarize the current understanding of the miR-15/107 family, focusing on its role in the regulation in the development of the heart and the progression of heart disease. We also discuss the potential of different members of the miR-15/107 family as biomarkers for diverse heart disease, as well as the current applications and challenges in the use of the miR-15/107 family in clinical trials for various disease. This paper hopes to explore the potential of the miR-15/107 family as therapeutic targets or biomarkers and to provide directions for future research.
心脏病是全球发病和死亡的主要原因之一。为降低心脏病患者的发病率和死亡率,识别药物靶点和生物标志物对于更有效的诊断、预后评估及治疗至关重要。微小RNA(miRNA)是一类内源性小非编码RNA,通过直接抑制靶基因发挥作用。miR-15/107家族是一组进化上保守的miRNA,由10个成员组成,它们共享AGCAGC的相同基序,这决定了重叠的靶基因以及在生物学过程中的协同作用。越来越多的证据表明,miR-15/107家族在心血管疾病、神经退行性疾病和癌症中存在明显的失调。在本综述中,我们总结了目前对miR-15/107家族的认识,重点关注其在心脏发育调节和心脏病进展中的作用。我们还讨论了miR-15/107家族不同成员作为多种心脏病生物标志物的潜力,以及在各种疾病临床试验中使用miR-15/107家族的当前应用和挑战。本文希望探索miR-15/107家族作为治疗靶点或生物标志物的潜力,并为未来研究提供方向。